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Because changes in cellcell adhesion have profound
e¡ects on cellular behavior, we hypothesized a link be-
tween the adhesion and signaling functions of plako-
globin and b-catenin. To investigate the existence of
adherens-junction-mediated signaling, we used peroxo-
vanadate to tyrosine phosphorylate plakoglobin and b-
catenin and to dissociate adherens junctions. The distri-
bution of plakoglobin and b-catenin was determined by
immuno£uorescence, western blot analysis, pulse-chase
radiolabeling, and biochemical subcellular fractiona-
tion. Coimmunoprecipitation studies from nuclear
fractions, gel-shift assays, and transient transfections
with T cell factor (TCF)/lymphoid enhancer factor
(LEF) optimized promoter reporter constructs were
used to investigate the ability of plakoglobin and b-ca-
tenin that had redistributed from the membrane to the
nucleus to form functional transcriptional regulatory
complexes with TCF/LEF family member transcription
factors. Tyrosine phosphorylation of plakoglobin and b-
catenin resulted in their rapid translocation from the
cell membrane to the nucleus. Nuclear translocation
was associated with increased plakoglobin and de-
creased b-catenin binding to nuclear TCF/LEF and
downregulation of gene transcription from TCF/LEF
reporter constructs. These results are consistent with a
signaling pathway initiated by structural changes in the
adherens junction in which adherens-junction-derived
plakoglobin regulates nuclear transcription by antago-
nizing the binding of b-catenin to TCF/LEF proteins.
Key words: adherens junction/b-catenin/phosphorylation/pla-
koglobin/signal transduction. J Invest Dermatol 121:242 ^251,
2003
I
n addition to their structural role in mediating adhesion,
both cellsubstrate and cellcell adhesion complexes are
thought to have functional roles as signaling proteins. For
example, changes in integrin-mediated adhesion activate
intracellular signaling cascades (for review see Giancotti
and Ruoslahti, 1999; Dedhar, 2000). Along with desmosomes
and tight junctions, adherens junctions function in epithelial
cellcell adhesion. In human keratinocytes, as in other epithelia,
components of the adherens junction include cadherins (Takeichi,
1988; Takeichi, 1991), b-catenin or plakoglobin, and a-catenin
(Ozawa et al, 1989; Nagafuchi et al, 1991; Butz and Kemler, 1994).
Recent studies have suggested that adherens junctions might also
function in signal transduction. Homophilic binding of the ex-
tracellular domain of cadherin has been shown to inhibit intracel-
lular RhoA GTPase activity and increase intracellular Rac1
GTPase activity (Noren et al, 2001). In tissue culture, overexpres-
sion of cadherin can downregulate the signaling function of b-
catenin by binding and sequestering b-catenin at the membrane
(Sadot et al, 1998; Simcha et al, 1998; Orsulic et al, 1999; Stockinger
et al, 2001).
In addition to its structural role in mediating cellcell adhe-
sion, b-catenin also functions in Wnt-mediated signal transduc-
tion (Funayama et al, 1995; Miller and Moon, 1996). The
cytoplasmic and nuclear levels of b-catenin are typically low due
to proteosome-mediated degradation (Aberle et al, 1997), which
requires the formation of a complex consisting of b-catenin, the
tumor suppressor protein adenomatous polyposis coli (Rubinfeld
et al, 1993; Su et al, 1993; Munemitsu et al, 1995), the serine/threo-
nine kinase glycogen synthetase kinase 3 (GSK-3) (Rubinfeld et al,
1996; Yost et al, 1996), and axin (Zeng et al, 1997; Ikeda et al, 1998).
Wnt proteins, a family of secreted polypeptides, bind to trans-
membrane frizzled receptors (Wang et al, 1996; He et al, 1997) on
cell membranes to initiate a signal transduction cascade that,
through the actions of disheveled, stabilizes cytoplasmic b-cate-
nin. Consequently, increased levels of b-catenin result in forma-
tion of bipartite transcription complexes between b-catenin and
the T cell factor (TCF)/lymphoid enhancer factor (LEF) family
transcription factors (Behrens et al, 1996; Molenaar et al, 1996; van
deWetering et al, 1997). The subsequent binding of nuclear-loca-
lized TCF/b-catenin complexes to DNA containing speci¢c
consensus sequences recognized by TCF/LEF family members
activates transcription of target genes including c-Myc (He et al,
1998) and cyclin D1 (Tetsu and McCormick, 1999). In keratino-
cyte epithelial biology, Wnt signaling has been implicated in
hair follicle development (van Genderen et al, 1994; Zhou
et al, 1995; DasGupta and Fuchs, 1999; Millar et al, 1999; Huelsken
et al, 2001; Merrill et al, 2001; Andl et al, 2002; Li et al, 2002)
and in maintenance of proliferative potential (Zhu and Watt,
1999).
Like b-catenin, plakoglobin binds to TCF/LEF proteins; how-
ever, plakoglobin’s signaling function is less clearly de¢ned. Be-
cause of their structural similarities, plakoglobin has been
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thought to function like b-catenin to activate transcription from
TCF/LEF response elements; however, in contrast to b-catenin,
which forms a ternary complex with LEF/TCF and DNA, Zhur-
insky and colleagues have shown that neither plakoglobinTCF4
nor plakoglobinLEF1 binary complexes bound DNA contain-
ing the optimized TCF/LEF promoter (Zhurinsky et al, 2000). In
cells transfected with plakoglobin cDNA, expression of plakoglo-
bin has been observed to increase the levels of nuclear and cyto-
plasmic b-catenin (Simcha et al, 1998; Williams et al, 2000). In
particular, membrane-anchored plakoglobin constructs, which
are themselves restricted from entry into the nuclei, increase nu-
clear and cytoplasmic b-catenin levels by saturating the degrada-
tive machinery and displacing b-catenin from the proteosome
targeting and degradation complexes (Miller and Moon, 1997).
Increased transcription from TCF reporter constructs that has
been observed in cells induced to overexpress plakoglobin is
probably due to the displacement of b-catenin by plakoglobin
from multiprotein cellular complexes; the displaced b-catenin is
then available for binding toTCF/LEF proteins with the resultant
formation of active transcriptional complexes. Recently, forma-
tion of a ternary complex between b-cateninTCF4 and plako-
globin has been described in which plakoglobin inhibits the
transcriptional activity of b-cateninTCF4 (Miravet et al, 2002).
The cellcell adhesion and signaling functions of plakoglobin
and b-catenin are generally thought to be independent because a
direct link between their adhesion and signaling functions has
not yet been demonstrated. Although several studies have re-
ported nuclear accumulation of catenins associated with catenin
phosphorylation or disruption of cellcell adhesion (Muller et al,
1999; Eger et al, 2000; Danilkovitch-Miagkova et al, 2001), none
has conclusively demonstrated that nuclear catenin is derived
from the membrane and not a result of new protein synthesis
and/or stabilization of cytoplasmic and nuclear catenin pools by
downregulation of proteosome-mediated degradation. In human
keratinocytes, tyrosine phosphorylation of plakoglobin and b-ca-
tenin disrupts cellcell adhesion and also disrupts the association
of these proteins with E-cadherin and a-catenin (Hu et al, 2001),
raising the possibility that b-catenin and plakoglobin released
from the adherens junction move to the nucleus to exert a signal-
ing function independent of Wnt binding to transmembrane
frizzled receptors. Because in vitro data demonstrate a low a⁄nity
of plakoglobinTCF/LEF complexes for TCF/LEF promoters
(Zhurinsky et al, 2000), the e¡ect of a coincident increase in nu-
clear b-catenin and nuclear plakoglobin, such as occurs upon dis-
sociation of keratinocyte adherens junctions, might be to either
activate or repress transcription fromTCF/LEF promoters.
In this report we demonstrate that tyrosine phosphorylation of
cell-membrane-associated plakoglobin results in (1) direct move-
ment (e.g., translocation) of plakoglobin from the cell membrane
to the nucleus, (2) increased nuclear localization of plakoglobin
and increased nuclear levels of complexes between TCF/LEF fa-
mily member transcription factors and plakoglobin, and (3) inhi-
bition of transcription from TCF/LEF reporter constructs.
Furthermore, nuclear coimmunoprecipitation studies suggest that
transcriptional inhibition by plakoglobin results from competi-
tion between nuclear-localized plakoglobin and b-catenin for
TCF/LEF proteins in which the binding of plakoglobin to TCF/
LEF proteins displaces b-catenin. These ¢ndings suggest a direct
signaling pathway from the adherens junction to the nucleus in-
itiated by changes in adherens junction structure and mediated
directly by plakoglobin released from the adherens junction by
tyrosine phosphorylation.
MATERIALS AND METHODS
Materials Monoclonal antibodies to human b-catenin and plakoglobin
(N-terminal), a horseradish peroxidase conjugated monoclonal
antiphosphotyrosine antibody (RC20-HRPO conjugate), a pan-
cytokeratin monoclonal antibody (clone AE1/AE3), and Protein G
Sepharose beads were from Zymed (San Francisco, CA). Monoclonal
antibodies to human E-cadherin, a C-terminal monoclonal antibody to
human plakoglobin, and a monoclonal antibody to poly ADP ribose
polymerase (PARP) were from Transduction Laboratories (Lexington,
KY). Anti-TCF/LEF (Pan) antibody, clone REMB6, was from Kamiya
Biomedical (Seattle, WA). A polyclonal anti-lactate dehydrogenase V
antibody was from Cortex Biochem (Sanleandro, CA). For western blot
detection, secondary goat antimouse horseradish peroxidase conjugated
IgG and enhanced chemiluminescence (ECL) reagents were from
Amersham Pharmacia Biotech (Buckinghamshire, UK). For immuno-
£uorescent staining, secondary £uorescein isothiocyanate and rhodamine
conjugated goat antihuman/rat/mouse IgG was from Jackson
ImmunoResearch Laboratories (West Grove, PA). [35S] methionine/
cysteine (1000 Ci per mM) and [a-32P] dATP (3000 Ci per mM) were
from ICN (Costa Mesa, CA). Electrophoresis reagents were from Bio-
Rad (Hercules, CA). Top£ash and Fop£ash reporter constructs were
obtained from Upstate Biotechnology (Lake Placid, NY). A control
vector was derived from the Top£ash reporter plasmid by excising the
TCF/LEF binding fragment (324 bp) with NdeI/SalI and subsequent re-
ligation of the vector plasmid. Wingless-conditioned medium was the
kind gift of Don McEwen and Mark Peifer (Department of Biology,
University of North Carolina  Chapel Hill, NC) (van Leeuwen
et al, 1994). All other reagents were of standard grade from Sigma (St
Louis, MO).
Tissue culture Primary human keratinocytes established from human
neonatal foreskins were obtained from Cascade Biologics (Portland, OR)
and cultured according to the recommended procedure using NHK 154
medium (0.2 mM CaCl2) supplemented with human keratinocyte growth
supplement (Cascade Biologics) and penicillin, streptomycin, and
amphotericin B (Cascade Biologics) according to the manufacturer’s
recommendations. Cells were expanded for two passages and frozen in
10% dimethylsulfoxide. Third passage keratinocytes were used for all
experiments. For immunoprecipitation experiments, cultures were grown
on Falcon 100 20 mm polystyrene Petri dishes to 80% con£uence. For
some experiments, cells were pretreated with LiCl (10 mM) or wingless-
conditioned medium for 8 h prior to harvesting or subsequent treatment
with peroxovanadate. SW480 colorectal adenocarcinoma cells were
obtained from the American Type Culture Collection (Manassas, VA) and
cultured according to the recommended procedures in Leibovitz’s L-15
medium supplemented with 2 mM L-glutamine and 10% fetal bovine
serum. Cells were treated with or without peroxovanadate (0.5 mM
Na3VO4, 3 mM H2O2) for 15 min prior to harvesting.
Confocal immuno£uorescent microscopy Immuno£uorescent
staining of human keratinocytes with monoclonal antibodies to
plakoglobin and b-catenin was as previously described (Hu et al, 2001).
Cells were treated with or without peroxovanadate (0.5 mM Na3VO4, 3
mM H2O2) for 15 min prior to ¢xation. Images were obtained using a
Zeiss laser scanning confocal microscope.
Subcellular fractionation Cell fractions were prepared according to
established protocols (Ausubel et al, 1995) with minor modi¢cations.
Brie£y, monolayer cells were quickly washed once with hypotonic bu¡er
(bu¡er A: 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol (DTT), 10 mM L-trans-epoxysuccinyl-leucylamide-(4-
guanidino)-butane N-[N-(L-3-transcarboxyirane-2-carbonyl)-L-leucyl]-
agmantine (E-64), 100 mM leupeptin, 10 mM pepstatin, and 1 mM
phenylmethylsulfonyl £uoride (PMSF)) and then were incubated with
bu¡er A on ice for 10 min. The cells were then scraped and the crude cell
lysates were dounced in a homogenizer with pestle A for 15 slow strokes
and centrifuged at 209g at 41C for 5 min in an Eppendorf benchtop
centrifuge. The supernatants (S1 fraction) were used for further extraction
of membrane and cytoplasmic fractions and the pellets (P1 fraction) were
used for nuclear fractions as follows.
S1 supernatant The supernatants were carefully transferred into clean tubes
and centrifuged at 100,000g at 41C for 1 h in a BeckmanTL100 ultracentri-
fuge. The supernatant from this centrifugation step was carefully trans-
ferred and saved as the cytoplasmic fraction. The pellets were washed with
hypotonic bu¡er twice and resuspended in lysis bu¡er (20 mM HEPES,
pH 7.9, 150 mM NaCl, 1.5 mMMgCl2, 0.2 mM ethylenediamine tetraacetic
acid (EDTA), 0.5 mM DTT, 1.0% Nonidet P-40, 10 mM E-64, 100 mM leu-
peptin, 10 mM pepstatin, and 1 mM PMSF), incubated at 41C for 1 h with
rotating, and then centrifuged at 13,700g 41C for 15 min to remove the in-
soluble material. The supernatant was collected and saved as the membrane
fraction. The insoluble pellet from this fraction was washed twice with ly-
sis bu¡er, resuspended by incubation in 8 M urea, 4% CHAPS, 10 mM
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TrisHCl, pH 7.4, with gentle rocking on a nutator for 1 h at 41C, and
centrifuged at 13,700g 41C for 15 min; the supernatants were saved as the
detergent insoluble fraction.
P1 pellets The pellets were washed with hypotonic bu¡er twice and resus-
pended in high salt bu¡er (20 mM HEPES, pH 7.9, 25% glycerol, 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 10 mM E-64, 100 mM
leupeptin, 10 mM pepstatin, and 1mM PMSF), incubated on ice for 20 min,
then dounced in a homogenizer with pestle B for 15 slow strokes, and cen-
trifuged at 13,700g the benchtop centrifuge at 41C for 20 min. The super-
natant was saved as nuclear fractions. Protein concentrations in all fractions
were determined by Bradford assay. The purity of each fraction was fol-
lowed by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblot detection with antibodies (dilutions) to
the transmembrane protein E-cadherin (1:2500), the cytoplasmic enzyme
lactate dehydrogenase (1:1000), the nuclear enzyme PARP (1:500), and the
cytoskeletal intermediate ¢lament protein keratin (AE1/AE3, 1:500) as mar-
kers of the detergent soluble membrane, cytoplasmic, nuclear, and deter-
gent insoluble fractions, respectively.
Immunoprecipitation Normal human keratinocytes or SW480 cells,
grown in tissue culture, were treated with or without peroxovanadate (0.5
mM Na3VO4, 3 mM H2O2), fractionated as described above, and subjected
to immunoprecipitation, as previously described (Hu et al, 2001), with the
following primary antibodies at the indicated concentrations: b-catenin
(Zymed, 0.5 mg antibody per 100 mg total protein), C-terminal
plakoglobin (Zymed, 0.5 mg antibody per 100 mg total protein), pan TCF/
LEF (1 mg antibody per 100 mg extract). Immunoprecipitated proteins were
separated by 7.5% SDS-PAGE (Laemmli, 1970), electrotransferred to
nitrocellulose, probed with primary antibodies (b-catenin 1:1000; N-
terminal plakoglobin 1:1000; antiphosphotyrosine 1:2500; C-terminal
plakoglobin 1:2000; TCF/LEF 1:250), and developed with horseradish
peroxidase conjugated secondary antibody and ECL reagents (Amersham)
as previously described (Hu et al, 2001). Horseradish peroxidase conjugated
antiphosphotyrosine antibodies were developed directly.
Pulse-chase analysis Keratinocytes were cultured to 80% con£uence
and incubated with medium containing [35S]-methionine/cysteine
overnight at 371C. Cells were washed once with cold medium and then
chased with cold medium for 4 h at 371C. Cells were then treated with or
without peroxovanadate (0.5 mM Na3VO4, 3 mM H2O2) for 15 min. Cells
were fractionated into membrane, cytoplasmic, and nuclear fractions, as
described above, and protein concentrations in each fraction were
determined by Bradford assay. Fractions containing equal amounts of
protein were subjected to immunoprecipitation followed by SDS-PAGE.
Quantitation of radioactivity in SDS-PAGE separated proteins was by
phosphoimage analysis of dried gels using a Molecular Dynamics
Phosphoimager and ImageQuant software.
TCF/LEF reporter assays Keratinocytes and SW480 cells, grown to
80% con£uence in 24-well plates, were transfected with 0.4 mg of the
Top£ash (Korinek et al, 1997) or Fop£ash reporter or control vectors using
the Lipofectamine Plus Reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. Twenty-four hours after transfection, the cells
were treated with (1) peroxovanadate (0.5 mM Na3VO4, 3 mM H2O2) for
15 min, (2) 10 mM LiCl for 8 h, (3) 10 mM LiCl for 8 h followed by
peroxovanadate for 15 min, (4) wingless-conditioned medium for 8 h, or
(5) wingless-conditioned medium for 8 h followed by peroxovanadate for
15 min, or (6) normal medium only for control. Luciferase activity was
measured using luciferase assay kits (Promega, Madison, WI) from six
parallel wells for each treatment condition; values were read using a
Lumat LB9501 luminometer (Berthold, Germany). Activities are expressed
as fold stimulation and are related to respective reporter activities obtained
with control vector plasmid, which retained the luciferase gene
downstream from a basal promoter but from which the TCF/LEF
optimized promoter had been excised.
Gel-shift assays Assays were performed as described previously
(Korinek et al, 1997) using the Amersham Pharmacia Bandshift kit. As the
optimal TCF probe, we used a 34-mer double-stranded oligonucleotide
AATTACTCTGGTACTGGCCCTTTGATCTTTCTGG. The mutant
TCF probe comprised a 34 -mer double-stranded oligonucleotide
AATTACTCTGGTACTGGCCCTTTCCGGTTTCTGG. Probes were
radiolabeled with [a-32P] dATP and Klenow according to the
manufacturer’s recommendations. Binding reactions were done with 5 mg
nuclear protein, 0.5 ng probe, 1 mg poly(dIdC), 10% glycerol, 0.05%
Nonidet P-40, 1 mM EDTA, 10 mM TrisHCl, pH 7.5, 50 mM NaCl, 0.5
mM DTT in a total 20 mL reaction volume.The samples were incubated for
20 min at room temperature. For supershift experiments, 0.5 mg of anti-b-
catenin or antiplakoglobin antibody (Transduction Laboratories) was added
and incubated for another 20 min. The samples were subsequently
subjected to 5% nondenaturing polyacrylamide gel electrophoresis.
RESULTS
Tyrosine phosphorylation of plakoglobin and b-catenin
results in a rapid redistribution of both plakoglobin and
b-catenin from the cell membrane to the nucleus. Keratino-
cytes incubated with the tyrosine phosphatase inhibitor peroxo-
vanadate demonstrated a rapid change in the distribution of both
plakoglobin and b-catenin. Confocal immuno£uorescent stain-
ing of plakoglobin and b-catenin in untreated keratinocytes was
predominantly localized to the cell membrane, whereas a shift in
staining to the cytoplasm and nucleus was observed in peroxova-
nadate-treated keratinocytes (Fig 1a). This change was more pro-
nounced for plakoglobin.
Biochemical fractionation of keratinocytes into detergent solu-
ble membrane, cytoplasmic, nuclear, and detergent insoluble
cytoskeletal fractions revealed similar results. Compared to con-
trol keratinocytes, increased amounts of plakoglobin and b-cate-
nin were detected by western blot analysis in the cytoplasmic
and nuclear fractions of peroxovanadate-treated keratinocytes
(Fig 1b). The lack of detectable E-cadherin, lactate dehydrogen-
ase, and keratin by western blot analysis of nuclear fractions de-
monstrated that nuclear fractions were not contaminated with
membrane, cytoplasmic, or cytoskeletal proteins, respectively.
The enzyme PARP, a marker for the nuclear compartment, was
detected only in nuclear extracts. Of note, cleavage of PARP, an
apoptosis-associated event, was observed in treated keratinocytes.
Additionally, the SDS-PAGE migration of plakoglobin and b-ca-
tenin from peroxovanadate-treated fractions was reduced, consis-
tent with their post-translational modi¢cation by
phosphorylation. Although not shown, when the ECL reaction
was allowed to continue so that the ¢lm became overdeveloped,
a small fraction of nontyrosine phosphorylated plakoglobin and
b-catenin, probably less than 5% of the nuclear pool, could be
detected.
In contrast to its ability to induce dissociation of plakoglobin
from adherens junctions (Hu et al, 2001), peroxovanadate-
mediated tyrosine phosphorylation of plakoglobin did not dis-
sociate plakoglobin from desmosomes. Unlike adherens junc-
tions, desmosomes are detergent insoluble. A marked reduction
in plakoglobin and b-catenin was observed in the detergent solu-
ble membrane fraction of peroxovanadate-treated cells; however,
using the detergent insoluble fraction as a marker for desmo-
somes (Pasdar and Nelson, 1988; 1989; Pasdar et al, 1995), we ob-
served no change between the amount of plakoglobin
immunoreactivity detected on western blots in the insoluble frac-
tion from control and from peroxovanadate-treated keratinocytes
(Fig 1b).
Immunoprecipitation of plakoglobin and b-catenin from nu-
clear fractions demonstrated increased levels of plakoglobin and
b-catenin in nuclei of peroxovanadate-treated cells compared to
controls. Additionally, the predominant isoforms of nuclear pla-
koglobin and b-catenin immunoprecipitated from peroxovana-
date-treated cells were tyrosine phosphorylated as revealed by
immunoblotting with antiphosphotyrosine antibodies (Fig 1c).
The membrane is the source of nuclear plakoglobin.The
increased amounts of nuclear-localized plakoglobin observed
after peroxovanadate treatment could be due to (1) release of pla-
koglobin from cell-membrane-localized adherens junctions, (2)
increased protein synthesis, or (3) stabilization of cytoplasmic pla-
koglobin by downregulation of cellular degradative pathways.
Pulse-chase labeling experiments were utilized to di¡erentiate
between these alternatives. Pulse-chase labeling enabled selective
labeling of junction-associated plakoglobin as nonjunction-
associated protein in the cytoplasm and nucleus was rapidly
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degraded; whereas, junction-associated protein persisted. After
incubation in the presence of medium containing [35S]-methio-
nine and [35S]-cysteine, 35S-labeled plakoglobin was detected in
membrane, cytoplasmic, and nuclear fractions (Fig 2, lane 1).
After being chased with cold medium for 4 h, there was a di¡er-
ential decrease in the levels of 35S-plakoglobin from each of these
three fractions, re£ective of the relative stability of plakoglobin in
these di¡erent cellular compartments. Cytoplasmic and nuclear
plakoglobin fractions were less stable than the membrane-asso-
ciated plakoglobin fraction; the cytoplasmic and nuclear fractions
represent 18.8% and 23.4% of the initial counts of these fractions,
respectively, whereas the membrane fraction decreased to 63% of
the initial counts (Fig 2, lane 2).
Subsequent treatment of 35S pulse-chase-labeled keratinocytes
with peroxovanadate resulted in redistribution of 35S-labeled pla-
koglobin from the membrane to the nucleus (Fig 2, lane 3). Re-
lative to the band density prior to peroxovanadate treatment (Fig
2, lane 2), the density of membrane 35S-plakoglobin decreased to
40% (lane 3 divided by lane 2); the cytoplasmic fraction showed a
modest increase (125%); however, the nuclear fraction of 35S-la-
beled plakoglobin showed an almost 4-fold increase (375%). Be-
cause it is not due to new protein synthesis, the increase in
nuclear plakoglobin is probably due to movement into the nu-
cleus of plakoglobin released from the membrane.
The translocation of plakoglobin from the membrane to
the nucleus results in the binding of nuclear plakoglobin to
TCF/LEF family members. Coimmunoprecipitation experi-
ments from nuclear extracts were used to determine if the ob-
served nuclear translocation resulted in complex formation
between TCF/LEF transcription factors and either plakoglobin
or b-catenin. After peroxovanadate treatment, increased levels of
both plakoglobin and b-catenin were detected in nuclear extracts;
the increase was more pronounced for plakoglobin (Fig 3a, N,V).
To enhance the catenin signal, keratinocytes were incubated in
the presence of LiCl prior to exposure to peroxovanadate. By in-
hibiting the serine/threonine kinase GSK-3, LiCl disrupts the de-
gradation of cytoplasmic b-catenin, allowing increased levels of
cytoplasmic and nuclear b-catenin to accumulate in the absence
of Wnt signaling (Klein and Melton, 1996; Stambolic et al, 1996).
Consistent with the e¡ects of LiCl in other cell types (Hedgepeth
et al, 1997), treating keratinocytes with LiCl resulted in increased
levels of nuclear plakoglobin and b-catenin (Fig 3a, L). When
keratinocytes that had been treated with LiCl were subsequently
treated with peroxovanadate for 15 min, nuclear plakoglobin and
b-catenin were markedly increased (Fig 3a, LþV); again, the in-
crease was more pronounced for plakoglobin.
To investigate the association of nuclear plakoglobin and b-ca-
tenin with TCF/LEF transcription factors, a pan-TCF/LEF anti-
body was used to immunoprecipitate TCF/LEF family members
from keratinocyte nuclear extracts and the immunoprecipitates
were probed for the presence of plakoglobin and b-catenin by
immunoblotting. Both plakoglobin and b-catenin coimmuno-
precipitated with TCF/LEF from nuclear extracts (Fig 3b, N).
Compared to nontreated control cells, more plakoglobin coim-
munoprecipitated with TCF/LEF from nuclear extracts of cells
treated with peroxovanadate; b-catenin similarly coimmunopre-
cipitated with TCF/LEF from nuclear extracts of both control
and peroxovanadate-treated cells. Furthermore, more plakoglobin
and b-catenin coimmunoprecipitated with TCF/LEF from nuclei
of LiCl-treated cells compared to controls. Relative to cells trea-
ted with LiCl alone, however, in keratinocytes treated ¢rst with
LiCl and then peroxovanadate, the amount of b-catenin coim-
munoprecipitating with nuclear TCF/LEF decreased, whereas
the amount of plakoglobin coimmunoprecipitating with nuclear
TCF/LEF increased (Fig 3b). This reciprocal relationship between
the ability of b-catenin and plakoglobin to coimmunoprecipitate
Figure1. Tyrosine phosphorylation of plakoglobin and b-catenin shifts their distribution from the membrane to the cytoplasm and nucleus.
(A) Confocal immuno£uorescent staining of cultured normal human keratinocytes for b-catenin or plakoglobin. Control cells (N) or cells treated with
peroxovanadate (V) for 15 min were ¢xed and immunohistochemically stained with monoclonal antibodies to b-catenin (b-cat) and plakoglobin (Plak) and
examined by confocal immuno£uorescent microscopy. (B) Subcellular fractionation. Control cells (N) or cells treated with peroxovanadate (V) for 15 min
were separated into detergent soluble membrane (Mem), cytoplasmic (Cyt), nuclear (Nuc), and detergent insoluble (Ins) fractions as described in Materials
and Methods. Ten micrograms from each fraction were separated by 7.5% SDS-PAGE, transferred to nitrocellulose, and immunoblotted with antibodies to
plakoglobin (Plak), b-catenin (b-cat), E-cadherin (E-cad), lactate dehydrogenaseV (LDH), polyADP ribose polymearse (PARP), and pan-cytokeratin (Ker).
Increased levels of plakoglobin and b-catenin were detected in the cytoplasmic and nuclear fractions of peroxovanadate-treated cells. (C) Immunoprecipita-
tion from nuclear fractions. Nuclear extracts from control cells (N) or cells treated with peroxovanadate (V) for 15 min were immunoprecipitated with
antibodies to plakoglobin (IP: Anti-Plak) and b-catenin (IP: Anti-b-cat) followed by immunoblot detection with antibodies to plakoglobin (IB: Plak) and
b-catenin (IB: b-cat), respectively. Blots were stripped and reprobed with antiphosphotyrosine antibodies (IB: Py).
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withTCF/LEF proteins from nuclear extracts suggests a competi-
tion between plakoglobin and b-catenin for binding toTCF/LEF
proteins in which plakoglobin binding to TCF/LEF might func-
tion to antagonize b-catenin-mediated transcriptional activation.
If the displacement of b-catenin fromTCF were due to a nonpla-
koglobin-related consequence of elevated tyrosine phosphoryla-
tion, decreased b-catenin binding to TCF/LEF would be
expected in SW480 cells, which express large amounts of nuclear
and cytoplasmic b-catenin. No decrease in binding of nuclear b-
catenin to TCF/LEF was observed in SW480 cells treated with
peroxovanadate, LiCl, or LiCl and peroxovanadate (Fig 3c), indi-
cating that the competition observed in keratinocytes is not the
result of a nonplakoglobin-related consequence of elevated tyro-
sine phosphorylation.
When coimmunoprecipitated withTCF/LEF from nuclear ex-
tracts of keratinocytes treated with LiCL and peroxovanadate,
plakoglobin immunoreactivity migrated on SDS-PAGE as a
doublet, suggesting that both tyrosine phosphorylated and non-
tyrosine phosphorylated plakoglobin bind to TCF/LEF family
members. Additionally, in these samples TCF/LEF coimmuno-
precipitated tyrosine and nontyrosine phosphorylated plakoglo-
bin in roughly equimolar concentrations. The observation that
the amount of nontyrosine phosphorylated plakoglobin in this
nuclear pool was signi¢cantly less than the amount of tyrosine
phosphorylated plakoglobin suggested an increased a⁄nity of
nontyrosine phosphorylated plakoglobin for TCF/LEF. The abil-
ity to visualize this species in the LiClþperoxovanadate treated
samples, but not in the peroxovanadate only treated samples was
probably due to the turnover of these proteins in the absence of
LiCl. Because of the dynamic equilibrium between cytoplasmic
and nuclear protein, both phosphorylated and nonphosphory-
lated protein are turned over. As there is much more tyrosine
phosphorylated protein, in the absence of LiCl the experiment is
biased towards detecting this species. When the degradation of
plakoglobin is decreased by LiCl, the less prevalent nonpho-
sphorylated species with the greater a⁄nity for TCF/LEF proteins
was visualized. These observations indicate that the e¡ect of
peroxovanadate-mediated tyrosine phosphorylation of plakoglo-
bin is due to its ability to induce the redistribution of plakoglo-
bin from the adherens junction to the nucleus and that the
increased amount of nuclear plakoglobin, and not tyrosine phos-
phorylation itself, is responsible for plakoglobin’s antagonism of
b-catenin.
DNA binding cateninTCF/LEF complexes are not
detected in nuclear extracts from peroxovanadate-treated
keratinocytes. Gel-shift experiments using the canonical TCF
binding site as a probe were used to assay for the presence of
DNA binding complexes in nuclear extracts. SW480 cells were
used as controls to check the speci¢city of the DNA probes. As
expected from previous reports (Korinek et al, 1997; Morin
et al, 1997), a shifted band was detected in SW480 nuclear extracts
when the TCF promoter sequence was used as a probe (Fig 4a,
lane 1); the signal from this band was markedly diminished
when extracts were incubated with the mutated probe demon-
strating speci¢city (Fig 4a, lane 2). Additionally, b-catenin
antibodies caused a supershift in the TCF probe (Fig 4a, lane 3)
Figure 2. The membrane is the source of nuclear plakoglobin. Keratinocytes were metabolically labeled with 35S methionine/cysteine overnight (1),
chased with cold medium for 4 h (2), and then treated with peroxovanadate (3) for 15 min. Cells were fractionated into detergent soluble membrane (MF),
cytoplasmic (CF), and nuclear fractions (NF). Plakoglobin was immunoprecipitated from 200 mg of each extract and separated by SDS-PAGE, and the
radioactivity in the plakoglobin band was quantitated by phosphoimage analysis. Each bar represents the average of three independent experiments; SEM
is shown by error bars. A representative phosphoimage scan of one such experiment is shown in the top panels. After incubation in the presence of medium
containing 35S-methionine and 35S-cysteine, 35S-labeled plakoglobin was detected in membrane, cytoplasmic, and nuclear fractions. After being chased
with cold medium for 4 h, there is a di¡erential decrease in the levels of 35S-plakoglobin from each of these three fractions re£ective of the relative stabi-
lity/turnover rate of plakoglobin in these di¡erent cellular compartments. Cytoplasmic and nuclear plakoglobin fractions are less stable than the membrane-
associated plakoglobin fraction. The cytoplasmic and nuclear fractions represent 18.8% and 23.4% of the initial counts of these fractions, respectively,
whereas the membrane fraction decreased to 63% of the initial counts (lane 1, 35S-plakoglobin after overnight labeling; lane 2, 35S-plakoglobin after over-
night labeling followed by 4 h chase with cold medium; lane 3, 35S-plakoglobin after overnight labeling followed by 4 h chase with cold medium and then
15 min incubation with peroxovanadate; MF, membrane fraction; CF, cytoplasmic fraction; NF, nuclear fraction). Subsequent treatment of 35S pulse-chase
labeled keratinocytes with peroxovanadate resulted in redistribution of 35S-labeled plakoglobin from the membrane to the nucleus (compare lanes 2 and 3).
Relative to the band density prior to peroxovanadate treatment, the density of membrane 35S-plakoglobin decreased to 40% (lane 3 divided by lane 2), and
the cytoplasmic fraction showed a modest increase (125%); however, the nuclear fraction of 35S-labeled plakoglobin showed almost a 4-fold increase (375%)
demonstrating that the increase in nuclear plakoglobin in peroxovanadate-treated cells is due to a redistribution of membrane-associated plakoglobin to the
nucleus.
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indicating the presence of b-catenin in the DNA binding
complex.
Examination of keratinocyte nuclear extracts revealed the pre-
sence of a DNA binding protein in nuclei of untreated controls
(Fig 4b, lane 1). Speci¢city for TCF binding sites was demon-
strated by the decreased signal when the Fop£ash mutant se-
quence probe was used (data not shown). This shifted band was
not detected in nuclear extracts of peroxovanadate-treated kerati-
nocytes (Fig 4b, lane 2). Supershift experiments with b-catenin
and plakoglobin antibodies failed to identify either of these pro-
teins in complex with DNA in nuclear extracts of control kerati-
nocytes (Fig 4b; lanes 3, 5, respectively). TheTCF promoter DNA
binding protein in nuclear extracts from control keratinocytes
may represent a repressor or, alternatively, it may represent b-ca-
teninTCF/LEF complexes, and the inability to detect a super-
shift with b-catenin antibodies may re£ect the low levels of b-
cateninprobe complexes in these extracts. Decreased binding
to DNAwas observed with peroxovanadate (Fig 4b, lane 2); how-
ever, no supershifts in nuclear extracts from peroxovanadate-trea-
ted keratinocytes were seen with either b-catenin or plakoglobin
antibodies (Fig 4b; lanes 4, 6, respectively) as would be expected
(1) if plakoglobinTCF/LEF complexes have low a⁄nity for
TCF reporter elements or (2) if plakoglobin competes with and
displaces the binding of b-catenin toTCF/LEF proteins.
Figure 3. Binding of nuclear plakoglobin and b-catenin toTCF/LEF
proteins. (A) Immunoblot detection of b-catenin and plakoglobin in nu-
clear extracts of keratinocytes. Ten micrograms of nuclear extract from
control (N), peroxovanadate-treated (V), LiCl-treated (L), and LiCl fol-
lowed by peroxovanadate treated (L þ V) keratinocytes separated by
SDS-PAGE and immunoblotted with antibodies to b-catenin (b-cat IB)
or plakoglobin (Plak IP). Increased levels of plakoglobin and b-catenin
were detected in nuclear extracts of peroxovanadate-treated keratinocytes
compared to controls. The migration of plakoglobin and b-catenin from
peroxovanadate-treated extracts is retarded consistent with tyrosine phos-
phorylation. Increased amounts of plakoglobin and b-catenin were de-
tected in nuclear extracts of cells treated with LiCl; however, no
retardation in their SDS-PAGE migration was observed. Exposure of kera-
tinocytes to LiCl and subsequent treatment with peroxovanadate results in
elevated nuclear levels of plakoglobin and b-catenin and their migration is
retarded. (B) TCF/LEF immunoprecipitations from human keratinocytes.
Two hundred micrograms of nuclear extracts from control (N), peroxova-
nadate-treated (V), LiCl-treated (L), and LiCl followed by peroxovanadate
treated (LþV) keratinocytes were subjected to immunoprecipitation with
a pan-TCF/LEF speci¢c monoclonal antibody, separated by SDS-PAGE,
and immunoblotted with antibodies to plakoglobin (Plak IB) and b-cate-
nin (b-cat IB). Both plakoglobin and b-catenin coimmunoprecipitated
with TCF/LEF from nuclear extracts of control (N) and peroxovanadate
(V) treated keratinocytes. More plakoglobin and b-catenin coimmunopre-
cipitated with TCF/LEF from nuclear extracts of cells pretreated with LiCl
(L). Compared to cells treated with only LiCl (L), more plakoglobin and
less b-catenin coimmunoprecipitated with TCF/LEF from nuclear extracts
of keratinocytes treated with LiCl followed by peroxovanadate (LþV). (C)
TCF/LEF immunoprecipitations from SW480 cells. TCF/LEF immuno-
precipitations from nuclear extracts of SW480 cells from control (N), per-
oxovanadate-treated (V), LiCl-treated (L), and LiCl followed by
peroxovanadate treated (LþV) cells were immunoblotted with antibodies
to plakoglobin (Plak IB) and b-catenin (b-cat IB). In contrast to keratino-
cytes, no reciprocal relationship is observed in plakoglobin’s and b-catenin’s
association with nuclear TCF/LEF proteins in SW480 cells treated with
LiCl and LiCl/peroxovanadate.
Figure 4. Gel-shift assays. Gel-shift assays were performed using nuclear
extracts from nontreated cells (N) or cells pretreated with peroxovanadate
for 15 min (V); DNA probes were either the 34 -mer double stranded DNA
containing the optimized TCF/LEF binding site (T) or the mutated bind-
ing site (F) as a control for speci¢c binding. For supershifts, 0.5 mg b-cate-
nin antibody was added to the samples in lane 3, panel A, and lanes 3^6,
panel B. (A) SW480 cells. A shifted band is seen when nuclear extracts from
SW480 cells were incubated with the TCF/LEF promoter sequence (T, lane
1), but not with the control mutated promoter (F, lane 2).When incubated
with b-catenin antibody, this band was supershifted (T, lane 3) indicating
the presence of DNA binding b-catenin^TCF/LEF complexes in nuclear
extracts of SW480 cells. (B) Keratinocytes. In nontreated keratinocytes (lane
1, N), a shifted band was identi¢ed using the probe containing the opti-
mized TCF/LEF binding site; this band was not seen when keratinocytes
were treated with peroxovanadate (lane 2,V). No supershift was seen when
nuclear extracts were ¢rst incubated with either b-catenin (lanes 3, 4) or
plakoglobin (lanes 5, 6) antibodies, indicating the absence of detectable b-
catenin^TCF/LEF^DNA and plakoglobin^TCF/LEF^DNA complexes in
either control (N) or peroxovanadate-treated (V) keratinocytes.
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A repressor of TCF/LEF promoter speci¢c transcription is
present in normal human keratinocytes To determine
whether increased nuclear levels of TCF/LEFcatenin
complexes could a¡ect the level of transcription from genes
containing TCF/LEF response elements, keratinocytes were
transiently transfected with TCF/LEF reporter constructs
containing an optimized TCF binding site (Top£ash) or a
mutant TCF binding site (Fop£ash) upstream of the luciferase
gene (Fig 5). For normal human keratinocytes, luciferase
activity was approximately an order of magnitude lower in
keratinocytes transfected with the Top£ash reporter than in those
transfected with Fop£ash (Fig 5a). This is the reverse situation
from what has been observed in cells in whichWnt signaling is
active. For example, because SW480 cells have high levels of
cytoplasmic and nuclear b-catenin, the signaling function of b-
catenin downstream of frizzled receptors is constitutively active;
therefore, SW480 colorectal carcinoma cells serve as useful
controls for this reporter assay. Consistent with published studies
(Korinek et al, 1997; Morin et al, 1997), high levels of luciferase
activity were detected in SW480 cells transfected with Top£ash
(Fig 5c); this activity was diminished 10-fold in SW480 cells
transfected with the Fop£ash construct containing the mutated
TCF/LEF promoter sequence. The observation that luciferase
activity in keratinocytes transfected with Top£ash and Fop£ash
was the reverse of what was observed in SW480 cells suggests
the presence in human keratinocytes of a repressor capable of
suppressing transcription from TCF/LEF optimized promoters,
although we have not excluded the possibility that keratinocytes
express an as yet unidenti¢ed transcriptional regulatory complex
that preferentially binds Fop£ash.
Negative regulation of gene transcription by TCF/LEF^
plakoglobin complexes When Top£ash-transfected keratinocytes
were treated with peroxovanadate, luciferase activity was essentially
unchanged (Fig 5b, cols N,V). In contrast to b-cateninTCF/LEF
complexes, plakoglobinTCF/LEF complexes do not e⁄ciently
bind DNA (Zhurinsky et al, 2000). The inability of
plakoglobinTCF/LEF to form high a⁄nity ternary complexes
with DNA suggested that one consequence of competition by
plakoglobin with b-catenin for binding to TCF/LEF proteins
might be downregulation of transcription from TCF/LEF
responsive genes. Because transcription from TCF/LEF responsive
promoters is repressed under the conditions of keratinocyte culture,
additional transcriptional repression due to competition by
plakoglobin for TCF/LEF might not be observed. To bypass these
constraints, keratinocytes were incubated in the presence of LiCl
prior to exposure to peroxovanadate. Consistent with the e¡ects of
LiCl in other cell types (Hedgepeth et al, 1997), increased luciferase
activity was observed when keratinocytes were cultured in the
presence of LiCl (Fig 5b, col L). Subsequent exposure of LiCl-
Figure 5. Changes in transcriptional activity from TCF/LEF reporter constructs. Normal human keratinocytes (NHK) and the human colorectal
carcinoma cell line SW480 were transiently transfected with the Top£ash reporter plasmid containing the TCF/LEF optimized promoter, the Fop£ash
control plasmid containing a mutated TCF/LEF promoter upstream of the luciferase gene, or a control plasmid that retained the luciferase gene downstream
from a basal promotor but from which the TCF/LEF optimized promoter had been excised (control vector). Each bar represents the average7standard
deviation of three independent experiments. (A) The amount of luciferase activity detected in normal human keratinocytes transfected with pTop£ash
was approximately 10% of the activity detected when keratinocytes were transfected with the mutated control plasmid pFop£ash, suggesting the presence
in keratinocytes of a repressor that binds with greater a⁄nity to the optimizedTCF/LEF promoter in pTop£ash than to the mutated promoter of the control
pFop£ash. (B) After treatment with peroxovanadate for 15 min (V), no increase in luciferase activity was observed compared to control keratinocytes (N).
Incubation of keratinocytes in the presence of LiCl resulted in increased luciferase activity (L). Subsequent peroxovanadate treatment of LiCl-treated kera-
tinocytes resulted in a more pronounced transcriptional repression than was observed for cells that had not been pretreated with LiCl; keratinocytes pre-
treated with LiCl and then subsequently treated with peroxovanadate for 15 min demonstrated a 4-fold reduction in luciferase activity (LþV). (C) SW480
human colorectal carcinoma cells transfected with either pTop£ash, pFop£ash, or control plasmid demonstrated the behavior expected for this cell line in
which b-catenin’s signaling function is constitutively active. Luciferase activity from pTop£ash was 10-fold higher than from pFop£ash. (D) No signi¢cant
di¡erence in pTop£ash reporter activity was seen between SW480 cells in the presence (V) or absence (N) of peroxovanadate, demonstrating that tyrosine
phosphorylation does not directly alter transcriptional activation by b-catenin^TCF/LEF complexes or other downstream components including the tran-
scriptional and translational machinery.
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treated keratinocytes to peroxovanadate resulted in an approximately
4-fold decrease in luciferase activity (Fig 5b, col LþV).
Binding of Wnt/Wg proteins to frizzled cell surface receptors
physiologically suppresses b-catenin degradation allowing
cytoplasmic and nuclear levels of b-catenin to rise and activate
transcription from TCF/LEF response elements. Incubation of
keratinocytes with wingless-conditioned medium provided a
second approach to activate downstream elements of Wnt
signaling prior to disruption of the adherens junction. Like LiCl,
incubation of keratinocytes with wingless-conditioned medium
resulted in increased luciferase activity. When keratinocytes ¢rst
incubated in the presence of wingless-conditioned medium were
subsequently exposed to peroxovanadate, a reduction in luciferase
activity was observed (Fig 5b, colsWg,WgþV) providing further
support for plakoglobin’s functional antagonism of b-catenin
TCF/LEF-mediated transcription.
Peroxovanadate is a potent inhibitor of tyrosine phosphatases and
augments the tyrosine phosphorylation of many cellular proteins
(Kadota et al, 1987; Ru¡ et al, 1997). Peroxovanadate-mediated
changes in TCF/LEF reporter activity might be a consequence of
nuclear translocated plakoglobin; alternatively, other molecular
events might be responsible, including direct e¡ects of
peroxovanadate on b-catenin’s binding to TCF/LEF, the interaction
of b-cateninTCF/LEF complexes with DNA, binding to
components of the basal transcription machinery, or transcription
and/or translation of luciferase. Therefore, it was necessary to
demonstrate that peroxovanadate was not a¡ecting other cellular
components that a¡ect transcription from the Top£ash reporter.
Analogous to keratinocytes pretreated with LiCl or wingless,
SW480 cells have elevated levels of cytoplasmic and nuclear
b-catenin (Rubinfeld et al, 1996; Korinek et al, 1997) and serve as
useful controls for activation of Wnt signaling components
downstream of frizzled receptors. If the decrease in TCF/LEF
reporter activity observed in keratinocytes were due to direct e¡ects
on b-catenin, TCF/LEF, or the transcriptional machinery, then
treating SW480 cells with peroxovanadate should similarly result in
decreased reporter activity. No signi¢cant di¡erence in luciferase
activity was observed between control and peroxovanadate-treated
SW480 cells (Fig 5d), however, indicating that peroxovanadate-
induced tyrosine phosphorylation does not directly a¡ect
components of Wnt signaling downstream of the cell surface.
DISCUSSION
Although the function of catenins in mediating Wnt signaling
downstream of transmembrane frizzled receptors is well estab-
lished, catenin signaling downstream of the adherens junction
Figure 6. A model for adherens junction signaling. (A) Although b-catenin is constitutively synthesized, its cytoplasmic and nuclear levels are kept
low by proteosome-mediated degradation through the targeting actions of a complex formed between APC, GSK-3, and axin. In the classicWnt signaling
pathway, the binding of Wnt proteins to frizzled transmembrane receptors initiates a signal that through the actions of dishevelled (dsh), suppresses APC/
GSK-3/axin activity. As a result, cytoplasmic and nuclear b-catenin accumulate, driving formation of a transcriptionally active complex between b-catenin
andTCF/LEF proteins. (B) Tyrosine phosphorylation of plakoglobin disrupts the adherens junction. Plakoglobin released from the adherens junction moves
from the membrane to the cytoplasm and nucleus where it competes with b-catenin for binding toTCF/LEF proteins. The displacement of b-catenin from
TCF/LEF proteins by plakoglobin forms transcriptionally inactive plakoglobin^TCF/LEF complexes resulting in functional antagonism of b-catenin-
mediatedWnt signaling.
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has not previously been demonstrated. In human keratinocytes,
we observed that peroxovanadate-mediated tyrosine phosphory-
lation of adherens-junction-associated plakoglobin resulted in (1)
the rapid translocation of plakoglobin from cell-membrane-loca-
lized adherens junctions to the nucleus, (2) increased binding of
plakoglobin toTCF/LEF proteins, and (3) inhibition of transcrip-
tion from TCF/LEF optimized promoters. These observations
support the concept of an additional signal transduction pathway
initiated by changes in adherens junction structure that is
mediated by redistribution of catenins from the adherens junc-
tion to the nucleus. In this pathway (Fig 6), disruption of b-cate-
nin’s and plakoglobin’s association with E-cadherin and a-catenin,
mediated by tyrosine phosphorylation, is followed by a rapid
translocation of plakoglobin and b-catenin to the nucleus. For
normal human keratinocytes in tissue culture, the e¡ect of this
translocation is a competition by plakoglobin with b-catenin for
binding toTCF/LEF family members.
As a consequence of translocation of adherens-junction-asso-
ciated plakoglobin to the nucleus, plakoglobin displaced b-cate-
nin binding and/or trapped free TCF/LEF proteins, preventing
the formation of functional transcriptional activation complexes
with DNA. Although TCF/LEFb-catenin complexes stimulate
transcription after binding to TCF/LEF promoters, TCF/LEF
plakoglobin complexes do not bind directly toTCF/LEF promo-
ters (Zhurinsky et al, 2000). Competition by plakoglobin with b-
catenin for binding to TCF/LEF proteins may be the mechanism
by which plakoglobin antagonized activation of transcription by
b-cateninTCF/LEF.
Signaling through the adherens junction may function to ‘‘in-
form’’ the cell of the changed state of adhesion, enabling cells to
communicate and change their behavior depending on the pre-
sence or absence of cellcell contact. In the absence of other sig-
nals, the e¡ect of loss of cell adhesion by disruption of the
adherens junction might be to block the transcriptional activation
by b-cateninTCF/LEF, thereby exerting an antiproliferative ef-
fect. Proliferation of nonadherent cells and the loss of contact in-
hibition often characterize malignant transformed cells. Thus, the
antiproliferative signal mediated by plakoglobin released from the
adherens junction might be one mechanism utilized by cells to
prevent continued proliferation in the absence of adhesion. This
would prevent proliferation of nonadherent cells as might occur
in malignant tumors. As there are conditions in which continued
proliferation of nonadherent or weakly adherent cells is of value,
e.g., during growth and development and wound repair, other
signals might impact on this pathway to regulate the balance of
plakoglobin/b-catenin binding to TCF/LEF transcription factors.
b-Catenin-mediated signaling is observed during proliferative
states; for example, stabilization of b-catenin and constitutive sig-
naling has been observed in a variety of malignant tumors (Kor-
inek et al, 1997; Morin et al, 1997; Rubinfeld et al, 1997; Fukuchi
et al, 1998; Miyoshi et al, 1998;Voeller et al, 1998). Additionally, in-
creased levels of cytoplasmic b-catenin staining have been identi-
¢ed in keratinocytes that give rise to the proliferative
compartment of the epidermis (Zhu andWatt, 1999).
If the physiologic role of adherens junction signaling mediated
by plakoglobin is to exert an antiproliferative e¡ect, the loss of
plakoglobin function might be associated with malignant trans-
formation.This appears to be the case as (1) loss of heterozygosity
in the plakoglobin gene has been reported in breast and ovarian
tumors consistent with a putative tumor suppressor role for pla-
koglobin (Aberle et al, 1995), (2) reduced plakoglobin mRNA and
protein levels have been identi¢ed in cervical carcinoma cell lines
(Denk et al, 1997), (3) relative to weakly invasive cell lines, highly
invasive breast cancer cell lines express decreased levels of plako-
globin (Sommers et al, 1994), (4) reduced plakoglobin expression
correlates with decreased disease free intervals and lower survival
rates in non-small cell lung cancer (Pantel et al, 1998), and (5) re-
duced expression of plakoglobin has been observed in pharyngeal
squamous cell carcinoma (Pukkila et al, 2001). Furthermore, trans-
fection of renal cell carcinoma cells with plakoglobin has been
shown to suppress their ability to form tumors in nude mice
(Simcha et al, 1996). Consistent with an antiproliferative role for
plakoglobin, overexpression of full length or N-terminally trun-
cated plakoglobin in murine skin reduces epidermal proliferation
and promotes apoptosis (Charpentier et al, 2000). Interestingly, we
observed cleavage of PARP in nuclei of peroxovanadate-treated
cells. PARP cleavage is a marker of apoptosis and may re£ect
one biologic consequence of plakoglobin’s antagonism of b-cate-
nin-mediatedWnt signaling. Despite these observations, in other
contexts, plakoglobin has been reported to have oncogenic po-
tential; Kolligs and coworkers have reported that plakoglobin
may behave as an oncogene in an adenovirus E1A-transformed
rat kidney epithelial cell line, possibly due to regulation of c-
Myc expression (Kolligs et al, 2000). Therefore, the physiologic
role of plakoglobin in activating or repressing signaling may be
both cell and context dependent.
In summary, we have demonstrated that plakoglobin, released
from the adherens junction, antagonizes b-catenin-mediatedWnt
signaling, downregulating transcription from TCF/LEF response
elements. The ¢nding of reduced plakoglobin expression in a
variety of tumors suggests that this signaling pathway is probably
of physiologic signi¢cance and may function to antagonize pro-
liferative signals when cellcell adhesion is lost.
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